Drug Trial Radar · NCT06699849
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Jul 10, 2025
Primary completion
Oct 22, 2027
Study completion Oct 22, 2027
Sponsor
- Lead sponsor
- CSL BehringIndustry
- Sponsor type
- Industry
- First posted
- Nov 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2, randomized, multiple-dose, placebo-controlled study designed to evaluate the safety, efficacy, and pharmacokinetics (PK) of CSL889 (human hemopexin) when given intravenously (IV) to adults and adolescents with sickle cell disease (SCD) experiencing vaso-occlusive crises (VOC). The main objectives of the study are to evaluate the safety and tolerability of CSL889 in study participants, and to assess how CSL889 affects the time it takes for VOC to resolve in participants with SCD.
Conditions
- Sickle Cell Disease Vaso-occlusive Crisis
Interventions
CSL889Biological
CSL889 is a solution for infusion to be administered by the IV route.
PlaceboDrug
Volume and regimen matched to CSL889 will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-emergent adverse events (TEAEs)Time frame: Up to Day 28 (End of study [EOS] Visit)
- Percentage of participants with TEAEsTime frame: Up to Day 28 (EOS Visit)
- Number of participants with detectable treatment emergent (TE) anti-CSL889 antibodiesTime frame: Up to Day 28 (EOS Visit)
- Percentage of participants with detectable TE anti-CSL889 antibodiesTime frame: Up to Day 28 (EOS Visit)
- Time to resolution of VOC (time to discontinuation of parenteral opioids)Time frame: Up to Day 28 (EOS Visit)
Locations
30 sites in 3 countries. Site status is shown where the registry gives one.
Univ. of California, San Francisco Health Care
Oakland, California · Recruiting
University of California Irvine
Orange, California · Recruiting
Medstar Washington Hospital Center
Washington D.C., District of Columbia · Recruiting
Golisano Children's Hospital
Fort Myers, Florida · Recruiting
The Foundation for Sickle Cell Disease
Hollywood, Florida · Recruiting
Arthur M. Blank Hospital-Children's Healthcare of Atlanta
Atlanta, Georgia · Recruiting
University of Illinois at Chicago
Chicago, Illinois · Recruiting
University of Louisville Hospital
Louisville, Kentucky · Recruiting
University of Maryland
Baltimore, Maryland · Recruiting
Detroit Medical Center
Detroit, Michigan · Recruiting
Henry Ford Health System
Detroit, Michigan · Recruiting
St. Louis Children's Hospital
St Louis, Missouri · Recruiting
Mount Sinai Medical Center
New York, New York · Recruiting
Jacobi Medical Center
The Bronx, New York · Recruiting
East Carolina University
Greenville, North Carolina · Recruiting
University of Cincinnati
Cincinnati, Ohio · Recruiting
The Ohio State University
Columbus, Ohio · Recruiting
University of Pittsburgh
Pittsburgh, Pennsylvania · Recruiting
Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
Virginia Commonwealth University
Richmond, Virginia · Withdrawn
Baskent University School of Medicine
Adana, Turkey (Türkiye) · Recruiting
Hacettepe Universitesi
Ankara, Turkey (Türkiye) · Recruiting
Istanbul Universitesi
Istanbul, Turkey (Türkiye) · Not yet recruiting
Medical Park Mersin Hospital
Mezitli-Mersin, Turkey (Türkiye) · Recruiting
Özel Acibadem Adana Hastanesi
Seyhan, Turkey (Türkiye) · Recruiting
Özel Acibadem Adana Hastanesi
Seyhan/Adana, Turkey (Türkiye) · Recruiting
Mersin Universitesi
Yenişehir, Turkey (Türkiye) · Recruiting
Royal Liverpool University Hospital
Liverpool, United Kingdom · Recruiting
University College London Hospitals NHS Trust
London, United Kingdom · Recruiting
Guy's Hospital
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.